Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
cancerGRACE - H. Jack West, MD
Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.
Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.
Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small cell lung cancer.
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early stage non-small cell lung cancer (NSCLC).
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.
Dr. David Harpole of Duke University reviews advances in lung cancer surgery, covering techniques ranging from video-assisted thoracic surgery to robotic surgery to sub-lobar resections and other developments offering new promising alternatives.
Dr. David Harpole of Duke University reviews advances in lung cancer surgery, focusing in this first part on the evolution of techniques to improve staging of lung cancer.
Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by EGFR inhibitors or chest radiation.
Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by chemotherapy commonly used for treating lung cancer.
Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.
Dr. Joel Neal presents interesting early data demonstrating that squamous NSCLC often features identifiable molecular markers that can potentially be targeted by novel therapies.
Dr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer.Â
Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.
Dr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).
Dr. Joel Neal describes the very encouraging data on anti-PD-1 immunotherapy with BMS-936558/MDX-1106 in patients with advanced non-small cell lung cancer (NSCLC).
Dr. Mark Socinski reviews key results in small cell lung cancer (SCLC) from ASCO 2012, including the SWOG 0802 trial of topotecan +/- VEGF inhibitor aflibercept and a Japanese randomized trial of cisplatin/amrubicin vs. cisplatin/irinotecan.
Dr. Mark Socinski from University of Pittsburgh summarizes and critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) in EGFR wild type advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.